FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2308277321> ?p ?o ?g. }

• W2308277321 endingPage "1607" @default.
• W2308277321 startingPage "1598" @default.
• W2308277321 abstract "// Vishnu C. Ramani 1, 2 , Fenghuang Zhan 3, 4 , Jianbo He 1 , Paola Barbieri 5 , Alessandro Noseda 5 , Guido Tricot 3, 4 , Ralph D. Sanderson 1, 2 1 Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA 2 Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA 3 Department of Internal Medicine, University of Iowa, Iowa City, IA, USA 4 Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA 5 Sigma-tau Research Switzerland S.A., Mendrisio, Switzerland Correspondence to: Ralph D. Sanderson, e-mail: sanderson@uab.edu Keywords: heparanase, multiple myeloma, roneparstat, drug resistance, chemotherapy Received: July 28, 2015      Accepted: November 16, 2015      Published: November 27, 2015 ABSTRACT In most myeloma patients, even after several rounds of intensive therapy, drug resistant tumor cells survive and proliferate aggressively leading to relapse. In the present study, gene expression profiling of tumor cells isolated from myeloma patients after sequential rounds of chemotherapy, revealed for the first time that heparanase, a potent promoter of myeloma growth and progression, was elevated in myeloma cells that survived therapy. Based on this clinical data, we hypothesized that heparanase was involved in myeloma resistance to drug therapy. In several survival and viability assays, elevated heparanase expression promoted resistance of myeloma tumor cells to chemotherapy. Mechanistically, this enhanced survival was due to heparanase-mediated ERK signaling. Importantly, use of the heparanase inhibitor Roneparstat in combination with chemotherapy clearly diminished the growth of disseminated myeloma tumors in vivo . Moreover, use of Roneparstat either during or after chemotherapy diminished regrowth of myeloma tumors in vivo following therapy. These results provide compelling evidence that heparanase is a promising, novel target for overcoming myeloma resistance to therapy and that targeting heparanase has the potential to prevent relapse in myeloma and possibly other cancers." @default.
• W2308277321 created "2016-06-24" @default.
• W2308277321 creator A5002787785 @default.
• W2308277321 creator A5007261675 @default.
• W2308277321 creator A5038705079 @default.
• W2308277321 creator A5040953545 @default.
• W2308277321 creator A5044466390 @default.
• W2308277321 creator A5065321890 @default.
• W2308277321 creator A5075208961 @default.
• W2308277321 date "2015-11-27" @default.
• W2308277321 modified "2023-10-16" @default.
• W2308277321 title "Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma" @default.
• W2308277321 cites W1571736940 @default.
• W2308277321 cites W1765663453 @default.
• W2308277321 cites W1896680896 @default.
• W2308277321 cites W1899693826 @default.
• W2308277321 cites W1968036059 @default.
• W2308277321 cites W1968152808 @default.
• W2308277321 cites W1976218313 @default.
• W2308277321 cites W1977877980 @default.
• W2308277321 cites W1982684154 @default.
• W2308277321 cites W1991286340 @default.
• W2308277321 cites W2010552629 @default.
• W2308277321 cites W2018242510 @default.
• W2308277321 cites W2020098579 @default.
• W2308277321 cites W2032599876 @default.
• W2308277321 cites W2050225501 @default.
• W2308277321 cites W2054402970 @default.
• W2308277321 cites W2055475863 @default.
• W2308277321 cites W2057090682 @default.
• W2308277321 cites W2063827408 @default.
• W2308277321 cites W2066616821 @default.
• W2308277321 cites W2070741299 @default.
• W2308277321 cites W2103289668 @default.
• W2308277321 cites W2104368170 @default.
• W2308277321 cites W2104551390 @default.
• W2308277321 cites W2121179180 @default.
• W2308277321 cites W2121317031 @default.
• W2308277321 cites W2155165473 @default.
• W2308277321 cites W2158608759 @default.
• W2308277321 cites W2164723344 @default.
• W2308277321 cites W2199761800 @default.
• W2308277321 doi "https://doi.org/10.18632/oncotarget.6408" @default.
• W2308277321 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4811483" @default.
• W2308277321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26624982" @default.
• W2308277321 hasPublicationYear "2015" @default.
• W2308277321 type Work @default.
• W2308277321 sameAs 2308277321 @default.
• W2308277321 citedByCount "73" @default.
• W2308277321 countsByYear W23082773212016 @default.
• W2308277321 countsByYear W23082773212017 @default.
• W2308277321 countsByYear W23082773212018 @default.
• W2308277321 countsByYear W23082773212019 @default.
• W2308277321 countsByYear W23082773212020 @default.
• W2308277321 countsByYear W23082773212021 @default.
• W2308277321 countsByYear W23082773212022 @default.
• W2308277321 countsByYear W23082773212023 @default.
• W2308277321 crossrefType "journal-article" @default.
• W2308277321 hasAuthorship W2308277321A5002787785 @default.
• W2308277321 hasAuthorship W2308277321A5007261675 @default.
• W2308277321 hasAuthorship W2308277321A5038705079 @default.
• W2308277321 hasAuthorship W2308277321A5040953545 @default.
• W2308277321 hasAuthorship W2308277321A5044466390 @default.
• W2308277321 hasAuthorship W2308277321A5065321890 @default.
• W2308277321 hasAuthorship W2308277321A5075208961 @default.
• W2308277321 hasBestOaLocation W23082773211 @default.
• W2308277321 hasConcept C121608353 @default.
• W2308277321 hasConcept C126322002 @default.
• W2308277321 hasConcept C143998085 @default.
• W2308277321 hasConcept C2776364478 @default.
• W2308277321 hasConcept C2776694085 @default.
• W2308277321 hasConcept C2777478136 @default.
• W2308277321 hasConcept C2779013556 @default.
• W2308277321 hasConcept C502942594 @default.
• W2308277321 hasConcept C71924100 @default.
• W2308277321 hasConceptScore W2308277321C121608353 @default.
• W2308277321 hasConceptScore W2308277321C126322002 @default.
• W2308277321 hasConceptScore W2308277321C143998085 @default.
• W2308277321 hasConceptScore W2308277321C2776364478 @default.
• W2308277321 hasConceptScore W2308277321C2776694085 @default.
• W2308277321 hasConceptScore W2308277321C2777478136 @default.
• W2308277321 hasConceptScore W2308277321C2779013556 @default.
• W2308277321 hasConceptScore W2308277321C502942594 @default.
• W2308277321 hasConceptScore W2308277321C71924100 @default.
• W2308277321 hasIssue "2" @default.
• W2308277321 hasLocation W23082773211 @default.
• W2308277321 hasLocation W23082773212 @default.
• W2308277321 hasLocation W23082773213 @default.
• W2308277321 hasLocation W23082773214 @default.
• W2308277321 hasOpenAccess W2308277321 @default.
• W2308277321 hasPrimaryLocation W23082773211 @default.
• W2308277321 hasRelatedWork W1539760658 @default.
• W2308277321 hasRelatedWork W1972583225 @default.
• W2308277321 hasRelatedWork W1979929833 @default.
• W2308277321 hasRelatedWork W1988887339 @default.
• W2308277321 hasRelatedWork W2086503905 @default.
• W2308277321 hasRelatedWork W2158352221 @default.
• W2308277321 hasRelatedWork W2370673941 @default.

• next